Leerink keeps Eli Lilly stock outperform on revenue growth
Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...
Hosted on MSN3h
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...
KB Home price target lowered to $76 from $85 at Keefe Bruyette
Keefe Bruyette analyst Jade Rahmani lowered the firm’s price target on KB Home (KBH) to $76 from $85 and keeps a Market Perform rating on the ...
Quanterix Buy Rating Supported by Instrument Sales Recovery, Strategic Growth Opportunities, and Promising Market Potential
Leerink Partners analyst Puneet Souda has maintained their bullish stance on QTRX stock, giving a Buy rating on January 15.Stay Ahead of the ...
Baird Q4 2024 International And Global Growth Fund Commentary
In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, ...
centerforbiosimilars22h
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...